Saurabh Naithani Profile picture
29.Full time investor and trader since 2012 in Indian equity market . Chemicals Pharma Index funds🙏😊
Oct 9, 2021 8 tweets 2 min read
#laurus labs business updates of last one year
Why #LAURUS is rising
Laurus has three segments
1.Generic Api
2.Generic FDF
3.Custom synthesis and ingredients
Generic Api almost 55% of business
First line products-Lamivudine, Dolutegravir Second line products-Lopinavir Ritonavir Darunavir
Dolutegravir launched in q4 fy20
Second line APIs will be launched in second half of this financial year
Generic FDF
Forms almost 36% of business
Received approval for TLE 400 and TLE600
Jun 10, 2021 4 tweets 1 min read
My learnings over the last 9 years in market:
1.Overtrading is a sin
2. Never Chase stock prices . Buy stocks which are undervalued. Which you will only know after reading and studying. Annual reports concalls are some best way to know the worth of a business. 3.Invest or trade in only what you know. Don't get into unwanted adventures
4. Be disciplined. Control your emotions. Never let greed takeover you.
5.Mistakes are necessary to keep going . Accept them and try not to repeat them.
6. Market and stocks are here to stay. Never regret
Oct 6, 2020 5 tweets 1 min read
Why #LAURUS is rising
Laurus has three segments
1.Generic Api
2.Generic FDF
3.Custom synthesis and ingredients
Generic Api almost 55% of business
First line products-Lamivudine, Dolutegravir
Second line products-Lopinavir Ritonavir Darunavir
Dolutegravir launched in q4 fy20 Second line APIs will be launched in second half of this financial year
Generic FDF
Forms almost 36% of business
Received approval for TLE 400 and TLE600
Europe- entered into long term partnership with a EU region for 1 billion units supply